Search the Newsreel

Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise

Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 2,500 shares at $1.01 per share and subsequently sold these 2,500 shares at a weighted average price of $16.0116. These transactions, executed under a Rule 10b5-1 trading plan adopted in September 2025, resulted in …

Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com

Contineum Therapeutics CEO Carmine N. Stengone sold 2,500 shares of the company's Class A Common Stock for $40,029 on August 3, 2026, through a pre-arranged 10b5-1 trading plan. On the same day, he also acquired 2,500 shares by exercising stock options for $2,525. The …

Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com

This article reports on a Form 4 filing for Contineum Therapeutics Inc. on August 3rd, as reported by Investing.com. It is a brief financial announcement indicating a regulatory disclosure for the company. The article includes standard market data and links to related financial news …

Contineum Therapeutics CEO Carmine Stengone disposes of shares worth $40,029

Contineum Therapeutics CEO Carmine N. Stengone sold 2,500 Class A common shares for $16.01 each on August 3, 2026, totaling $40,029. On the same day, he acquired 2,500 shares via option exercise at $1.01 per share. This transaction resulted in a decrease in his …

Contineum Therapeutics, Inc. $CTNM Position Increased by Janus Henderson Group PLC

Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM

RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.1% - Should You Sell?

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics reported its second-quarter 2026 financial results, affirming key clinical development milestones for its drug candidates. The company is focusing its resources on inflammatory and fibrotic diseases, including the global Phase 2 PROPEL-IPF trial for PIPE-791 and Johnson & Johnson's completed enrollment for …

CTNM|Contineum Therapeutics Inc|Price:15.040|Chg%:-0.310

Contineum Therapeutics (CTNM) Projected to Announce Earnings on Tuesday

BlackRock (CTNM stakeholder) reports 2.0M-share beneficial position in Therapeutics Inc

BlackRock, Inc. has filed a Schedule 13G, disclosing a 6.3% beneficial ownership in Contineum Therapeutics Inc.'s Class A stock, totaling 2,049,493 shares. BlackRock primarily holds sole voting power over 2,030,054 shares and sole dispositive power over all 2,049,493 shares. This stake is held on …

Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise, Stock Pulls Back - Dividend Cut Risk

Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth

Contineum Therapeutics (NASDAQ:CTNM), despite being unprofitable, has seen its share price rise 265% in the last year. The company has a cash runway of about 4.3 years based on its US$246m cash and US$58m annual cash burn, indicating a comfortable position for future development. …

Contineum Therapeutics (CTNM) stake at 2.8% in Millennium 13G/A update

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported a beneficial ownership of 931,709 shares of Contineum Therapeutics, Inc.'s Class A common stock, representing a 2.8% stake. This information was disclosed in an amended Schedule 13G filing, indicating shared voting …

Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ: CTNM) Stock Price, News & Analysis

Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership

Contineum Therapeutics has updated its corporate strategy, emphasizing PIPE-791 as its lead LPAR1 antagonist for idiopathic pulmonary fibrosis and chronic pain. The company plans to defer CTX-343 development until dedicated funding is secured and relies on a partnership with Janssen for PIPE-307, projecting a …

CTNM Forecast — Price Target — Prediction for 2027

CTNM Q1 2026 Earnings: EPS Surprises with Narrower Loss, Stock Advances 2.5% - Analyst Coverage Count

CTNM Q1 2026 Earnings: Loss Narrows on EPS Beat, Pipeline Progress Maintains Focus - Tangible Book Value

CTNM Q1 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Maintains Discipline - Earnings Call Highlights

Contineum Therapeutics, Inc. (CTNM)